Traumatic brain injury, neuroinflammation, and post-traumatic headaches

Headache

Volumn 53, Issue 9, 2013, Pages 1523-1530

  Mayer, Cynthia L ^a,b   Huber, Bertrand R ^a   Peskind, Elaine ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

astrocytes; blood brain barrier; cytokines, post traumatic headaches; glia; inflammation; inflammatory mediators; microglia; satellite cells; traumatic brain injury

Indexed keywords

CHEMOKINE; CYTOKINE;

ARTICLE; ASTROCYTE; GLIA CELL; HUMAN; MICROGLIA; NERVE CELL EXCITABILITY; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; POSTTRAUMATIC HEADACHE; PRIORITY JOURNAL; TRAUMATIC BRAIN INJURY;

ASTROCYTES; BLOOD BRAIN BARRIER; CYTOKINES, POST-TRAUMATIC HEADACHES; GLIA; INFLAMMATION; INFLAMMATORY MEDIATORS; MICROGLIA; SATELLITE CELLS; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN INJURIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; NEUROGLIA; POST-TRAUMATIC HEADACHE;

EID: 84885190635     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12173     Document Type: Article

References (143)

1. Faul M, Xu L, Wald M, Coronado V,. Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations, and Deaths. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
2. National Center for Injury Prevention and Control. Report to Congress on Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem. Atlanta, GA: Centers for Disease Control and Prevention; 2003.
3. Iverson GL,. Outcome from mild traumatic brain injury. Curr Opin Psychiatry. 2005; 18: 301-317.
4. Hoffman JM, Lucas S, Dikmen S, et al. Natural history of headache after traumatic brain injury. J Neurotrauma. 2011; 28: 1719-1725.
5. Nampiaparampil DE,. Prevalence of chronic pain after traumatic brain injury: A systematic review. JAMA. 2008; 300: 711-719.
6. Couch JR, Bearss C,. Chronic daily headache in the posttrauma syndrome: Relation to extent of head injury. Headache. 2001; 41: 559-564.
7. Baandrup L, Jensen R,. Chronic post-traumatic headache-a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia. 2005; 25: 132-138.
8. Bekkelund SI, Salvesen R,. Prevalence of head trauma in patients with difficult headache: The North Norway Headache Study. Headache. 2003; 43: 59-62.
9. Haas DC,. Chronic post-traumatic headaches classified and compared with natural headaches. Cephalalgia. 1996; 16: 486-493.
10. Lucas S, Hoffman JM, Bell KR, Walker W, Dikmen S,. Characterization of headache after traumatic brain injury. Cephalalgia. 2012; 32: 600-606.
11. Radanov BP, Di Stefano G, Augustiny KF,. Symptomatic approach to posttraumatic headache and its possible implications for treatment. Eur Spine J. 2001; 10: 403-407.
12. Ruff RL, Ruff SS, Wang XF,. Headaches among Operation Iraqi Freedom/Operation Enduring Freedom veterans with mild traumatic brain injury associated with exposures to explosions. Rehabil Res Dev. 2008; 45: 941-952.
13. Theeler BJ, Flynn FG, Erickson JC,. Headaches after concussion in US soldiers returning from Iraq or Afghanistan. Headache. 2010; 50: 1262-1272.
14. Walker WC, Seel RT, Curtiss G, Warden DL,. Headache after moderate and severe traumatic brain injury: A longitudinal analysis. Arch Phys Med Rehabil. 2005; 86: 1793-1800.
15. Theeler BJ, Erickson JC,. Post-traumatic headaches: Time for a revised classification? Cephalalgia. 2012; 32: 589-591.
16. Ziebell JM, Morganti-Kossmann MC,. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics. 2010; 7: 22-30.
17. Morganti-Kossmann MC, Rancan M, Stahel PF, Kossmann T,. Inflammatory response in acute traumatic brain injury: A double-edged sword. Curr Opin Crit Care. 2002; 8: 101-105.
18. Konrad C, Geburek AJ, Rist F, et al. Long-term cognitive and emotional consequences of mild traumatic brain injury. Psychol Med. 2011; 41: 1197-1211.
19. Ponsford J, Cameron P, Fitzgerald M, Grant M, Mikocka-Walus A,. Long-term outcomes after uncomplicated mild traumatic brain injury: A comparison with trauma controls. J Neurotrauma. 2011; 28: 937-946.
20. Kraus J, Schaffer K, Ayers K, Stenehjem J, Shen H, Afifi AA,. Physical complaints, medical service use, and social and employment changes following mild traumatic brain injury: A 6-month longitudinal study. J Head Trauma Rehabil. 2005; 20: 239-256.
21. McIntosh TK, Saatman KE, Raghupathi R, et al. The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: Pathogenetic mechanisms. Neuropathol Appl Neurobiol. 1998; 24: 251-267.
22. Xiong Y, Gu Q, Peterson PL, Muizelaar JP, Lee CP,. Mitochondrial dysfunction and calcium perturbation induced by traumatic brain injury. J Neurotrauma. 1997; 14: 23-34.
23. Hall ED, Detloff MR, Johnson K, Kupina NC,. Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury. J Neurotrauma. 2004; 21: 9-20.
24. Yakovlev AG, Knoblach SM, Fan L, Fox GB, Goodnight R, Faden AI,. Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury. J Neurosci. 1997; 17: 7415-7424.
25. Andriessen TM, Jacobs B, Vos PE,. Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med. 2010; 14: 2381-2392.
26. Morganti-Kossmann MC, Satgunaseelan L, Bye N, Kossmann T,. Modulation of immune response by head injury. Injury. 2007; 38: 1392-1400.
27. Loane DJ, Byrnes KR,. Role of microglia in neurotrauma. Neurotherapeutics. 2010; 7: 366-377.
28. Nimmerjahn A, Kirchhoff F, Helmchen F,. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005; 308: 1314-1318.
29. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005; 8: 752-758.
30. Block ML, Zecca L, Hong JS,. Microglia-mediated neurotoxicity: Uncovering the molecular mechanisms. Nat Rev Neurosci. 2007; 8: 57-69.
31. Wolf Y, Yona S, Kim KW, Jung S,. Microglia, seen from the CX3CR1 angle. Front Cell Neurosci. 2013; 7: 26.
32. Olah M, Biber K, Vinet J, Boddeke HW,. Microglia phenotype diversity. CNS Neurol Disord Drug Targets. 2011; 10: 108-118.
33. Hanisch UK, Kettenmann H,. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007; 10: 1387-1394.
34. Block ML, Hong JS,. Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism. Prog Neurobiol. 2005; 76: 77-98.
35. Gao HM, Hong JS,. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol. 2008; 29: 357-365.
36. Sperlagh B, Illes P,. Purinergic modulation of microglial cell activation. Purinergic Signal. 2007; 3: 117-127.
37. Perry VH, Nicoll JA, Holmes C,. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010; 6: 193-201.
38. Pierce JE, Smith DH, Trojanowski JQ, McIntosh TK,. Enduring cognitive, neurobehavioral and histopathological changes persist for up to one year following severe experimental brain injury in rats. Neuroscience. 1998; 87: 359-369.
39. Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH,. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol. 2004; 165: 357-371.
40. Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W,. Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain. 2013; 136: 28-42.
41. Smith C, Gentleman SM, Leclercq PD, et al. The neuroinflammatory response in humans after traumatic brain injury. Neuropathol Appl Neurobiol. 2012 (forthcoming).
42. Chen XH, Johnson VE, Uryu K, Trojanowski JQ, Smith DH,. A lack of amyloid beta plaques despite persistent accumulation of amyloid beta in axons of long-term survivors of traumatic brain injury. Brain Pathol. 2009; 19: 214-223.
43. Gentleman SM, Leclercq PD, Moyes L, et al. Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int. 2004; 146: 97-104.
44. Christman CW, Grady MS, Walker SA, Holloway KL, Povlishock JT,. Ultrastructural studies of diffuse axonal injury in humans. J Neurotrauma. 1994; 11: 173-186.
45. Povlishock JT, Becker DP, Cheng CL, Vaughan GW,. Axonal change in minor head injury. J Neuropathol Exp Neurol. 1983; 42: 225-242.
46. Blumbergs PC, Scott G, Manavis J, Wainwright H, Simpson DA, McLean AJ,. Topography of axonal injury as defined by amyloid precursor protein and the sector scoring method in mild and severe closed head injury. J Neurotrauma. 1995; 12: 565-572.
47. Browne KD, Chen XH, Meaney DF, Smith DH,. Mild traumatic brain injury and diffuse axonal injury in swine. J Neurotrauma. 2011; 28: 1747-1755.
48. Masel BE, DeWitt DS,. Traumatic brain injury: A disease process, not an event. J Neurotrauma. 2010; 27: 1529-1540.
49. Strich SJ,. Diffuse degeneration of the cerebral white matter in severe dementia following head injury. J Neurol Neurosurg Psychiatry. 1956; 19: 163-185.
50. Bigler ED,. Neuroinflammation and the dynamic lesion in traumatic brain injury. Brain. 2013; 136: 9-11.
51. Nedergaard M, Ransom B, Goldman SA,. New roles for astrocytes: Redefining the functional architecture of the brain. Trends Neurosci. 2003; 26: 523-530.
52. Abbott NJ, Ronnback L, Hansson E,. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006; 7: 41-53.
53. Stobart JL, Anderson CM,. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front Cell Neurosci. 2013; 7: 38.
54. Pekny M, Nilsson M,. Astrocyte activation and reactive gliosis. Glia. 2005; 50: 427-434.
55. Scemes E, Giaume C,. Astrocyte calcium waves: What they are and what they do. Glia. 2006; 54: 716-725.
56. Choo AM, Miller WJ, Chen YC, et al. Antagonism of purinergic signalling improves recovery from traumatic brain injury. Brain. 2013; 136: 65-80.
57. Gao YJ, Ji RR,. Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 2010; 7: 482-493.
58. Gosselin RD, Suter MR, Ji RR, Decosterd I,. Glial cells and chronic pain. Neuroscientist. 2010; 16: 519-531.
59. Cafferty WB, Yang SH, Duffy PJ, Li S, Strittmatter SM,. Functional axonal regeneration through astrocytic scar genetically modified to digest chondroitin sulfate proteoglycans. J Neurosci. 2007; 27: 2176-2185.
60. Yiu G, He Z,. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci. 2006; 7: 617-627.
61. Zamanian JL, Xu L, Foo LC, et al. Genomic analysis of reactive astrogliosis. J Neurosci. 2012; 32: 6391-6410.
62. Kumar A, Loane DJ,. Neuroinflammation after traumatic brain injury: Opportunities for therapeutic intervention. Brain Behav Immun. 2012; 26: 1191-1201.
63. Emery B, Butzkueven H, Snell C, Binder M, Kilpatrick TJ,. Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience. 2006; 137: 463-472.
64. Soldan MM, Pirko I,. Biogenesis and significance of central nervous system myelin. Semin Neurol. 2012; 32: 9-14.
65. Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012; 487: 443-448.
66. Hanani M,. Satellite glial cells in sensory ganglia: From form to function. Brain Res Brain Res Rev. 2005; 48: 457-476.
67. Thalakoti S, Patil VV, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache. 2007; 47: 1008-1023; discussion 1024-1005.
68. Jasmin L, Vit JP, Bhargava A, Ohara PT,. Can satellite glial cells be therapeutic targets for pain control? Neuron Glia Biol. 2010; 6: 63-71.
69. Ohara PT, Vit JP, Bhargava A, et al. Gliopathic pain: When satellite glial cells go bad. Neuroscientist. 2009; 15: 450-463.
70. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ,. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010; 37: 13-25.
71. Neuwelt EA, Bauer B, Fahlke C, et al. Engaging neuroscience to advance translational research in brain barrier biology. Nat Rev Neurosci. 2011; 12: 169-182.
72. Chodobski A, Zink BJ, Szmydynger-Chodobska J,. Blood-brain barrier pathophysiology in traumatic brain injury. Transl Stroke Res. 2011; 2: 492-516.
73. Shlosberg D, Benifla M, Kaufer D, Friedman A,. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010; 6: 393-403.
74. Pop V, Badaut J,. A neurovascular perspective for long-term changes after brain trauma. Transl Stroke Res. 2011; 2: 533-545.
75. Habgood MD, Bye N, Dziegielewska KM, et al. Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice. Eur J Neurosci. 2007; 25: 231-238.
76. Tomkins O, Shelef I, Kaizerman I, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry. 2008; 79: 774-777.
77. Korn A, Golan H, Melamed I, Pascual-Marqui R, Friedman A,. Focal cortical dysfunction and blood-brain barrier disruption in patients with postconcussion syndrome. J Clin Neurophysiol. 2005; 22: 1-9.
78. Kubes P, Ward PA,. Leukocyte recruitment and the acute inflammatory response. Brain Pathol. 2000; 10: 127-135.
79. Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM,. Neutrophil accumulation after traumatic brain injury in rats: Comparison of weight drop and controlled cortical impact models. J Neurotrauma. 1994; 11: 499-506.
80. Abbott NJ, Friedman A,. Overview and introduction: The blood-brain barrier in health and disease. Epilepsia. 2012; 53 (Suppl. 6): 1-6.
81. Soares HD, Hicks RR, Smith D, McIntosh TK,. Inflammatory leukocytic recruitment and diffuse neuronal degeneration are separate pathological processes resulting from traumatic brain injury. J Neurosci. 1995; 15: 8223-8233.
82. Lee SJ, Benveniste EN,. Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol. 1999; 98: 77-88.
83. Owens T, Bechmann I, Engelhardt B,. Perivascular spaces and the two steps to neuroinflammation. J Neuropathol Exp Neurol. 2008; 67: 1113-1121.
84. Hellewell SC, Morganti-Kossmann MC,. Guilty molecules, guilty minds? The conflicting roles of the innate immune response to traumatic brain injury. Mediators Inflamm. 2012; 2012: 356494.
85. Helmy A, De Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ,. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011; 95: 352-372.
86. Frugier T, Morganti-Kossmann MC, O'Reilly D, McLean CA,. In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J Neurotrauma. 2010; 27: 497-507.
87. Helmy A, Antoniades CA, Guilfoyle MR, Carpenter KL, Hutchinson PJ,. Principal component analysis of the cytokine and chemokine response to human traumatic brain injury. PLoS ONE. 2012; 7: e39677.
88. Maas AI, Roozenbeek B, Manley GT,. Clinical trials in traumatic brain injury: Past experience and current developments. Neurotherapeutics. 2010; 7: 115-126.
89. Fan L, Young PR, Barone FC, Feuerstein GZ, Smith DH, McIntosh TK,. Experimental brain injury induces expression of interleukin-1 beta mRNA in the rat brain. Brain Res Mol Brain Res. 1995; 30: 125-130.
90. Woodcock T, Morganti-Kossmann MC,. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013; 4: 18.
91. Chao CC, Hu S, Ehrlich L, Peterson PK,. Interleukin-1 and tumor necrosis factor-alpha synergistically mediate neurotoxicity: Involvement of nitric oxide and of N-methyl-D-aspartate receptors. Brain Behav Immun. 1995; 9: 355-365.
92. de Vries HE, Blom-Roosemalen MC, van Oosten M, et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol. 1996; 64: 37-43.
93. Mark KS, Miller DW,. Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. Life Sci. 1999; 64: 1941-1953.
94. Marchand F, Perretti M, McMahon SB,. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005; 6: 521-532.
95. Watkins LR, Milligan ED, Maier SF,. Spinal cord glia: New players in pain. Pain. 2001; 93: 201-205.
96. Swartz KR, Liu F, Sewell D, et al. Interleukin-6 promotes post-traumatic healing in the central nervous system. Brain Res. 2001; 896: 86-95.
97. Penkowa M, Moos T, Carrasco J, et al. Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia. 1999; 25: 343-357.
98. Kremlev SG, Palmer C,. Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J Neuroimmunol. 2005; 162: 71-80.
99. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G,. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol. 2001; 22: 147-184.
100. Deshmane SL, Kremlev S, Amini S, Sawaya BE,. Monocyte chemoattractant protein-1 (MCP-1): An overview. J Interferon Cytokine Res. 2009; 29: 313-326.
101. Miller RJ, Jung H, Bhangoo SK, White FA,. Cytokine and chemokine regulation of sensory neuron function. Handb Exp Pharmacol. 2009; 194: 417-449.
102. Gosselin RD, Dansereau MA, Pohl M, et al. Chemokine network in the nervous system: A new target for pain relief. Curr Med Chem. 2008; 15: 2866-2875.
103. Thacker MA, Clark AK, Bishop T, et al. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009; 13: 263-272.
104. Lakhan SE, Avramut M,. Matrix metalloproteinases in neuropathic pain and migraine: Friends, enemies, and therapeutic targets. Pain Res Treat. 2012; 2012: 952906.
105. Rosenberg GA, Yang Y,. Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus. 2007; 22: E4.
106. Rosenberg GA, Cunningham LA, Wallace J, et al. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: Activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res. 2001; 893: 104-112.
107. Milligan ED, Watkins LR,. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009; 10: 23-36.
108. Vilalta A, Sahuquillo J, Poca MA, et al. Brain contusions induce a strong local overexpression of MMP-9. Results of a pilot study. Acta Neurochir Suppl. 2008; 102: 415-419.
109. Imamura K, Takeshima T, Fusayasu E, Nakashima K,. Increased plasma matrix metalloproteinase-9 levels in migraineurs. Headache. 2008; 48: 135-139.
110. Martins-Oliveira A, Goncalves FM, Speciali JG, et al. Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine. J Neuroimmunol. 2012; 252: 89-94.
111. Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ,. Clinical relevance of cortical spreading depression in neurological disorders: Migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab. 2011; 31: 17-35.
112. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004; 113: 1447-1455.
113. Tsuda M, Tozaki-Saitoh H, Inoue K,. Purinergic system, microglia and neuropathic pain. Curr Opin Pharmacol. 2012; 12: 74-79.
114. Hughes JP, Hatcher JP, Chessell IP,. The role of P2X(7) in pain and inflammation. Purinergic Signal. 2007; 3: 163-169.
115. Downes CE, Crack PJ,. Neural injury following stroke: Are Toll-like receptors the link between the immune system and the CNS? Br J Pharmacol. 2010; 160: 1872-1888.
116. Olson JK, Miller SD,. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol. 2004; 173: 3916-3924.
117. Carpentier PA, Duncan DS, Miller SD,. Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun. 2008; 22: 140-147.
118. Packard RC,. Epidemiology and pathogenesis of posttraumatic headache. J Head Trauma Rehabil. 1999; 14: 9-21.
119. Bernstein C, Burstein R,. Sensitization of the trigeminovascular pathway: Perspective and implications to migraine pathophysiology. J Clin Neurol. 2012; 8: 89-99.
120. Ji RR, Kawasaki Y, Zhuang ZY, Wen YR, Decosterd I,. Possible role of spinal astrocytes in maintaining chronic pain sensitization: Review of current evidence with focus on bFGF/JNK pathway. Neuron Glia Biol. 2006; 2: 259-269.
121. Tsuda M, Inoue K, Salter MW,. Neuropathic pain and spinal microglia: A big problem from molecules in "small" glia. Trends Neurosci. 2005; 28: 101-107.
122. McMahon SB, Malcangio M,. Current challenges in glia-pain biology. Neuron. 2009; 64: 46-54.
123. Fischer M, Wille G, Klien S, et al. Brain-derived neurotrophic factor in primary headaches. J Headache Pain. 2012; 13: 469-475.
124. Capuano A, De Corato A, Lisi L, Tringali G, Navarra P, Dello Russo C,. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: Relevance for migraine pathology. Mol Pain. 2009; 5: 43.
125. Raddant AC, Russo AF,. Calcitonin gene-related peptide in migraine: Intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011; 13: e36.
126. Uceyler N, Schafers M, Sommer C,. Mode of action of cytokines on nociceptive neurons. Exp Brain Res. 2009; 196: 67-78.
127. Franceschini A, Vilotti S, Ferrari MD, van den Maagdenberg AM, Nistri A, Fabbretti E,. TNFalpha levels and macrophages expression reflect an inflammatory potential of trigeminal ganglia in a mouse model of familial hemiplegic migraine. PLoS ONE. 2013; 8: e52394.
128. White FA, Jung H, Miller RJ,. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A. 2007; 104: 20151-20158.
129. Xie YF,. Glial involvement in trigeminal central sensitization. Acta Pharmacol Sin. 2008; 29: 641-645.
130. Takeda M, Takahashi M, Matsumoto S,. Contribution of the activation of satellite glia in sensory ganglia to pathological pain. Neurosci Biobehav Rev. 2009; 33: 784-792.
131. Ren K,. Neuron, glia, and reciprocal relationships in pain processing. Open Pain J. 2009; 2: 7-31.
132. Ren K,. Emerging role of astroglia in pain hypersensitivity. Jpn Dent Sci Rev. 2010; 46: 86.
133. Packard RC, Ham LP,. Pathogenesis of posttraumatic headache and migraine: A common headache pathway? Headache. 1997; 37: 142-152.
134. Sofroniew MV, Vinters HV,. Astrocytes: Biology and pathology. Acta Neuropathol. 2010; 119: 7-35.
135. Ricci G, Volpi L, Pasquali L, Petrozzi L, Siciliano G,. Astrocyte-neuron interactions in neurological disorders. J Biol Phys. 2009; 35: 317-336.
136. Charles A,. Migraine: A brain state. Curr Opin Neurol. 2013; 26: 235-239.
137. Bo SH, Davidsen EM, Gulbrandsen P, et al. Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia. 2009; 29: 365-372.
138. Kocer A, Kocer E, Memisogullari R, Domac FM, Yuksel H,. Interleukin-6 levels in tension headache patients. Clin J Pain. 2010; 26: 690-693.
139. Rozen T, Swidan SZ,. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007; 47: 1050-1055.
140. Martelletti P,. Proinflammatory pathways in cervicogenic headache. Clin Exp Rheumatol. 2000; 18: S33-S38.
141. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
142. Engel S, Schluesener H, Mittelbronn M, et al. Dynamics of microglial activation after human traumatic brain injury are revealed by delayed expression of macrophage-related proteins MRP8 and MRP14. Acta Neuropathol. 2000; 100: 313-322.
143. Oberheim NA, Takano T, Han X, et al. Uniquely hominid features of adult human astrocytes. J Neurosci. 2009; 29: 3276-3287.